OncLive TV

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses targeted therapies and mutations in chronic lymphocytic leukemia.

Robert Dreicer, MD, MS, from the Cleveland Clinic in Ohio, discusses a 2-weeks-on and 1-week-off (2/1) schedule of sunitinib for patients with metastatic renal cell carcinoma.

José Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, discusses treatment with PIK3CA inhibitors in patients with breast cancer.

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the relationship between risk and treatment in patients with multiple myeloma.

Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses tumor heterogeneity in patients with breast cancer.

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, details the difference between EPOCH-R and R-CHOP chemotherapy.

Howard M. Sandler, MD, the Chair of Radiation Oncology at Cedars-Sinai Medical Center, discusses radium-223, a novel alpha radiation emitting agent under evaluation by the FDA for patients with bone metastases from advanced castration-resistant prostate cancer (CRPC).

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses the development of metagene prognostic signatures for patients with breast cancer.

Mark D. Pegram, MD, from the Stanford Cancer Institute, describes research into the antibody-drug conjugate T-DM1, following its FDA approval in February as a treatment for HER2-positive metastatic breast cancer.

Meir Wetzler, MD, Chief, Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, discusses a study presented at the 2012 American Society of Hematology Meeting analyzing arsenic trioxide in acute promyelocytic leukemia.

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the information currently available on sequencing the recently approved treatments for men with metastatic castration-resistant prostate cancer.

J. Michael Dixon, MBChB, MD, Professor of Surgery, Consultant Surgeon, University of Edinburgh, Clinical Director of the Edinburgh Breast Unit, Western General Hospital, Edinburgh, Scotland, discusses the discrepancy in the rate of mastectomies.

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the long-term experience from the COMFORT-I and COMFORT-II trials in myelofibrosis.

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, discusses the future of chemotherapy in patients with lymphomas.

Emanuel "Chip" Petricoin III, PhD, from George Mason University, discusses the inability of DNA and RNA profiling to predict response to treatment with targeted therapies.

Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, discusses the relationship between sipuleucel-T and time to first use of an opioid analgesic in patients with metastatic castration-resistant prostate cancer.

George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, discusses measuring mutations in human cancers quantitatively.

Robert Dreicer, MD, MS, from the Taussig Cancer Institute at the Cleveland Clinic, describes potential combination therapies currently being considered as treatments for men with prostate cancer.

Bruce D. Cheson, MD, from Georgetown Lombardi Comprehensive Cancer Center, discusses the prospect of using antibody drug conjugates in non-Hodgkin lymphomas, including follicular lymphoma.

Abigail S. Caudle, MD, Assistant Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, describes the ACOSOG Z1071 study in breast cancer.

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses active surveillance as a treatment approach for men with prostate cancer.

Patrick Borgen, MD, from the Maimonides Breast Cancer Center, details the factors that go into a patient's decision to undergo a mastectomy.

Harry Erba, MD, PhD, from the University of Alabama at Birmingham, discusses the use of second-generation tyrosine kinase inhibitors for the treatment of chronic phase chronic myeloid leukemia.

Gunter von Minckwitz, MD, PhD, Chairman, German Breast Group, Professor of Gynecology, University of Frankfurt, Germany, discusses pathologic complete response (pCR) and outcomes.

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, Chief Executive Officer, Oncotherapeutics, discusses the a study of carfilzomib as a replacement for bortezomib for multiple myeloma patients refractory to a bortezomib-containing combination regimen.

Hyman B. Muss, MD, Professor of Medicine, Director of Geriatric Oncology, Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill School of Medicine, on the need for geriatric assessments.

Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses combination therapies in cutaneous T-cell lymphoma.

Hugo Ford, MD, from the Addenbrooke's Hospital in Cambridge, UK, describes which patients with metastatic esophagogastric cancer derive the greatest benefit from second-line treatment with docetaxel.

Matthew Cooperberg, MD, MPH, from the University of California, San Francisco, discusses the imminent stage migration that is likely to occur as new therapies become available expressly for metastatic prostate cancer.

Anees Chagpar, MD, MSc, MA, MPH, Associate Professor of Surgery (Oncology), Director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, discusses the need for repeat biopsy in patients with breast cancer.